Wegovy maker Novo sharpens consumer focus with board role for Mars CEO - Reuters

Novo Nordisk, the pharmaceutical company behind the blockbuster weight-loss drug Wegovy, has appointed Mars CEO to its board, signaling a strategic shift toward strengthening its consumer-facing business. The move reflects Novo's ambition to expand beyond its traditional pharmaceutical roots and deepen expertise in consumer marketing and brand management as obesity and diabetes drugs become increasingly mainstream. Mars, one of the world's largest private companies with extensive consumer goods experience, brings valuable operational knowledge to a drugmaker navigating the competitive landscape of GLP-1 medications. The appointment underscores how Novo is positioning itself not just as a pharmaceutical manufacturer but as a consumer health company competing in a rapidly growing market. This reflects broader industry trends as weight-loss medications transition from niche treatments to mass-market products.